Combination of protease inhibitors for the treatment of HIV-1-infected patients: A review of pharmacokinetics and clinical experience

Antiviral Therapy

Volumn 6, Issue 4, 2001, Pages 201-229

  Van Heeswijk, R P G ^a   Veldkamp, A I ^a   Mulder, J W ^a   Meenhorst, P L ^a   Lange, J M A ^a   Beijnen, J H ^a   Hoetelmans, R M W ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CYTOCHROME P450 3A4; GLYCOPROTEIN P; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MIXED FUNCTION OXYGENASES; P-GLYCOPROTEIN; RITONAVIR;

EID: 0035717630     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (246)

1. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA Panel
2. Clinical pharmacology of HIV protease inhibitors: Focus on saquinavir, indinavir, and ritonavir
3. Treatment with indinavir (IDV), zidovudine (AZT) and lamivudine (3TC): Three-year follow-up
4. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
5. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
6. Indinavir. A review of its use in the management of HIV infection
7. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
8. Nelfinavir. An update on its use in HIV infection
9. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine
10. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents
11. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
12. Steady-state pharmacokinetic interactions between ritonavir (RTV), nelfinavir (NFV), and the nelfinavir active metabolite (M8) (AG1402)
13. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection
14. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals
15. Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir
16. Adherence to antiretroviral therapy: The physician's perspective
17. Adherence to antiretroviral therapy: The patient's perspective
18. Meta-analysis of the effectiveness of triple combination therapy in antiretroviral naive HIV-1 infected adults
19. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
20. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type-1-infected persons
21. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
22. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug interactions
23. Are three drugs enough? Baseline viral load as a predictor of virologic response to triple therapy
24. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy
25. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection
26. The effect of prescribed daily dose frequency on patient medication compliance
27. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
28. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
29. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy
30. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy
31. Relationships between antiviral treatment effects and biphasic viral decay rates in modelling HIV dynamics
32. Plasma concentrations of saquinavir (SQV) determine HIV-1 response over a 48-week period
33. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy
34. Pharmacodynamics (PD) of indinavir (IDV) inprotease-naive HIV-infected patients receiving ZDV and 3TC
35. The addition of a second protease inhibitor eliminates amprenavirefavirenz drug interactions and increases plasma amprenavir concentrations
36. Differences in pharmacokinetics (PK) of saquinavir soft-gelatin capsules (SQV-sgc, Fortovase) after a normal and high fat breakfast
37. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple dosing
38. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
39. Protease inhibitors in patients with HIV disease
40. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4
41. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir
42. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction
43. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir, and indinavir
44. Pharmacokinetic interactions between HIV-protease inhibitors in rats
45. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
46. In vitro inhibition of cytochrome P450 2D6 and 3A4 by HIV protease inhibitors
47. Prediction of nelfinavir mesylate (Viracept) clinical drug interactions based on in vitro human P450 metabolism studies
48. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions
49. Inhibition and induction of cytochrome P450 and the clinical implications
50. Characterisation of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate
51. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
52. Lack of pharmacokinetic interaction between nelfinavir and nevirapine
53. A study of the pharmacokinetics of repetitive dosing with nelfinavir
54. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors
55. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
56. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
57. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
58. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells
59. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
60. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins
61. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor
62. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
63. Cellular localisation of the multi-resistance gene product P-glycoprotein in normal human tissues
64. The pharmacological role of P-glycoprotein in the intestinal epithelium
65. Limited oral bioavailability and active epithelial secretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
66. Co-administration of cyclosporin enables oral therapy with paclitaxel
67. Coadministration of oral cyclosporine A enables oral therapy with paclitaxel
68. Saquinavir absorption: Role of P-glycoprotein
69. P-glycoprotein limits oral bioavailability, brain and fetal penetration of saquinavir even with high-dose ritonavir
70. Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type-1
71. Antiretroviral drugs and the central nervous system
72. Sanctuary sites in HIV-1 infection
73. 14C] saquinavir in normal and P-glycoprotein (Pgp) deficient mice and cultured cells
74. The Prometheus study: Double protease inhibitor (PI) treatment only is unable to suppress detectable viral load in the CSE
75. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir
76. The concentrations of D4T, 3TC, nelfinavir (NFV) and saquinavir (SQV) in plasma, cerebrospinal fluid (CSF), and semen
77. Poor penetration of the male genital tract by HIV-1 protease inhibitors
78. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex
79. Indinavir-based treatment of HIV-1 infected patients: Efficacy in the central nervous system
80. Effect of ketoconazole, the P-glycoprotein inhibitor, on ritonavir and saquinavir plasma and cerebrospinal fluid concentrations
81. Human serum a1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A80987, an inhibitor of the human immunodeficiency virus type 1 protease
82. May the drug transporter P-glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors?
83. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
84. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeffciency virus type 1 protease inhibitors in tissue culture
85. Cellular influx/efflux of protease inhibitors in vitro
86. In vitro and in vivo protease inhibitor (PI) kinetics in human cell line expressing or not MDR1. Role of ritonavir (RI) in intracellular PI accumulation
87. Differences in intracellular drug accumulation between protease inhibitors
88. Synergistic anti-HIV activity of ritonavir and other protease inhibitors in the presence of human serum
89. Ritonavir-containing dual protease inhibitor regimens may have synergistic antiviral effects in patients - Based on in vitro model
90. Activities of the human immunodeficency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro
91. Indinavir-saquinavir single dose pharmacokinetic study
92. Antagonism between the human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro
93. Resistance, fitness, adherence, and potency. Mapping the paths to virologic failure
94. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study
95. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
96. A randomised trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
97. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
98. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
99. Managing resistance to anti-HIV drugs. An important consideration for effective disease management
100. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
101. Recent developments in HIV protease inhibitor therapy
102. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
103. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
104. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
105. Resistance to human immunodeficiency virus type 1 protease inhibitors
106. Analysis of cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies
107. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates
108. Simultaneous use of two protease inhibitors in HIV infection
109. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study
110. The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring
111. Therapeutic drug monitoring of protease inhibitors: What to measure and when
112. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir
113. Therapeutic drug monitoring of protease-inhibitors during HAART with one or a combination of two PI
114. ATHENA: A randomised, control ed clinical trial to evaluate whether therapeutic drug monitoring (TDM) contributes to reduced HIV-related morbidity and mortality
115. Relevance of protease inhibitor plasma levels in patients treated with genotypic adapted therapy: Pharmacological data from the Viradapt study
116. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
117. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt: A prospective multicentric randomized controlled trial: 12 Weeks results
118. Simultaneous determination of ritonavir and saquinavir, two human immunodeficiency virus protease inhibitors, in human serum by high-performance liquid chromatography
119. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection
120. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography
121. High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir in plasma of patients during highly active antiretroviral therapy
122. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction
123. Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma
124. Current knowledge and future prospects for the use of HIV protease inbibitors
125. Predictors of virologic response and subsequent failure to five different initial protease inhibitor treatment regimens
126. Saquinavir soft gel capsule (Fortovase): Pharmacokinetics and drug interactions
127. Ritonavir (RTV) low dosages increases dramatically the saquinavir (SQV-HGC) bioavailability: A PK study in healthy volunteers
128. Three-year follow-up analysis and conditional outcome survival analysis of ritonavir (RTV) plus saquinavir (SQV) therapy in HIV infection
129. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
130. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients
131. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in HIV patients (CTN 117)
132. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients
133. Tolerability of ritonavir vs. ritonavir/saquinavir: A retrospective study
134. Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg
135. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomised trial
136. Reduced dose ritonavir (RTV) compared with standard-dose RTV in protease inhibitor naive (PI) naive subjects
137. Assessment of single- and multiple dose interactions between ritonavir and saquinavir
138. The effect of ritonavir on increases in saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of 120 subjects
139. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir
140. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture
141. Ritonavir enables combined therapy with rifampin and saquinavir
142. Tuberculosis in patients with human immunodeficiency virus infection
143. Drug interactions of HIV protease inhibitors
144. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
145. Pharmacokinetics of the triple combination of saquinavir, ritonavir, and efavirenz in HlV-positive patients
146. The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
147. Iris study: Ritonavir/saquinavir (RTV/SQV) + 1 NRTI versus indinavir (IDV) + 2 NRTIs: One year follow-up
148. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
149. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
150. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: Results from a community-based study
151. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens
152. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals
153. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
154. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
155. Failure of a ritonavir plus saquinavir-based rescue regimen precludes the use of protease inhibitors
156. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients
157. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low-dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
158. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
159. Indinavir can be taken with regular meals when administered with ritonavir
160. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) ritonavir (RTV) combinations in healthy volunteers
161. Ritonavir intensification in indinavir recipients with detectable HIV RNA levels
162. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: Pharmacokinetics, safety, and efficacy
163. Increased incidence of indinavir-associated nephrolithiasis in a warm climate
164. Combining ritonavir (RTV) & indinavir (IDV) decreases IDV-associated urinary & renal adverse events
165. Virologic & immunologic response to combination protease inhibitor therapy with ritonavir (RTV) & indinavir (IDV) inantiretroviral naive HIV + patients
166. BID first-line ritonavir/indinavir 48 weeks results: German Multicenter study
167. Saquinavir (SQV) pharmacokinetics in combination with nelfinavir (NFV) in the ADAM study
168. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients
169. Effect of nelfinavir on short and long-term plasma exposure of saquinavir in hard gel capsule during tid and bid dosing regimens
170. The SPICE study: 48-Week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of protease inhibitor combinations in Europe
171. TIDBID study 48 weeks analysis: Fortovase (FTV) TID regimen compared to FTV BID or FTV+NFV BID regimens in HIV-1-infected patients
172. Efficacy and safety of bid and tid regimens of nelfinavir (NFV) + saquinavir (SQV) + stavudine (d4T) + lamivudine (3TC) in HIV-infected women: 48-Week results of the Women's First study
173. A retrospective study of the safety, efficacy, and tolerability of ritonavir/indinavir 400/400 mg bid versus indinavir 800 mg q8h
174. Final analysis of ritonavir intensification in indinavir recipients with detectable HIV RNA levels
175. Resistance to HIV-1protease inhibitors and predicted responses to therapy
176. Salvage therapy with ritonavir + indinavir regimens is more durable than ritonavir + saquinavir regimens after nelfinavir failure
177. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy
178. Activity of the combination of nelfinavir and saquinavir against human immunodeficiency virus after failure of prior protease inhibitor therapy
179. Efficacy of salvage therapy containing nelfinavir and saquinavir after failure of single protease inhibitor containing regimens
180. Efficacy of salvage therapy containing nelfinavir/saquinavir combination and their correlation with genotypic resistance pattern
181. Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks
182. Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficency virus-infected patients with chroniv liver disease
183. The influence of low doses of ritonavir on the pharmacokinetics of nelfinavir 1250 mg bid
184. Co-administration of indinavir and nelfinavir in a twice daily regimen: Preliminary safety, pharmacokinetic and anti-viral activity results
185. Co-administration of indinavir 1000 mg and with escalating nelfinavir dose in a twice daily regimen: Preliminary safety, pharmacokinetic and anti-viral activity
186. Co-administration of indinavir and nelfinavir: Pharmacokinetics, tolerability, anti-viral activity, and preliminary viral resistance
187. Rate of onset of hyperlipidaemia following treatment with ritonavir/saquinavir and correlation with drug levels
188. Lipid profiles in patients on ritonavir/indinavir containing salvage regimens
189. Diagnosis, prediction, and natural course of HIV-1 protease-inhibtor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
190. Once daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals. A pharmacokinetic pilot study
191. Modulation of saquinavir steady-state pharmacokinetics with "baby" doses of ritonavir in healthy volunteers
192. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir
193. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
194. Long term efficacy of saquinavir and ritonavir low dosage (baby-dose) in HIV patients failing combination therapy: Correlation of response to treatment with genotypic mutations and pharmacologic data
195. Pharmacokinetics of an indinavir/ritonavir 800/100 bid regimen
196. Combination therapy with indinavir and ritonavir in antiretroviral-experienced patients
197. Enhance penetration of indinavir (IDV) in cerebrospinal fluid and semen after addition of low-dose ritonavir
198. Dose-finding study of a once-daily indinavir/ritonavir regimen
199. Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients
200. Multiple-dose pharmacokinetics (PK) and tolerability of indinavir (IDV) and ritonavir (RTV) combinations in a once-daily regimen in healthy volunteers (Merck 089)
201. Safety and efficacy of amprenavir in combination with other HIV protease inhibitors
202. Agenerase in dual PI combination therapy with saquinavir, indinavir, or nelfinavir: Emergence of resistance
203. A randomised, placebo-controlled trial of saquinavir (SQV-SGC), indinavir (IDV), or nelfinavir (NFV) in combination with amprenavir (AMP), abacavir (ABC), efavirenz (EFZ), & adefovir (ADV) in patients (Pts) with protease inhibitor (PI) failure
204. Pharmacokinetic (PK) drug-interaction between amprenavir (AMP) and ritonavir (RTV) in HIV seronegative subjects after multiple dosing
205. Amprenavir (APV) and ritonavir (RTV): Intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmacokinetics in HIV-1-infected patients
206. Amprenavir (APV) shows less protease inhibitor (PI) cross resistance as compared with other PIs in a multiexperienced HIV cohort (CNAB3008, French virological substudy)
207. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
208. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir
209. Multiple-dose pharmacokinetics (PK) of ABT-378/ritonavir (ABT-378/r) in HIV+ subjects
210. Evaluation of the pharmacokinetics of the concurrent administration of ABT-378/ritonavir and nevirapine
211. A randomized study comparing continued indinavir (800 mg tid) vs switching to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleoside analogues. The BID efficacy and safety trial (BEST)
212. Indinavir/ritonavir vs indinavir in combination with AZT/3TC for treatment of HIV in nucleoside-experienced patients: A randomised, open-label trial
213. ABT-378/ritonavir (ABT-378/r) in antiretroviral naive HIV + patients: 72 Weeks
214. ABT-378/ritonavir (ABT-378/r) suppresses HIV RNA to < 400 copies/mL in 84% of PI-experienced patients at 48 weeks
215. Once-daily dosing of 1,600 mg saquinavir (soft-gelatin capsules; SQV-SGC) plus low dose ritonavir (RTV; 100 mg) in HIV-1-infected Thai patients: Pharmacokinetics and clinical experience (HIV-NAT 001.3)
216. Pharmacokinetic and safety evaluation of a once daily regimen of saquinavir soft-gelatin capsules (SQV) in HIV infected antiretroviral naive patients
217. Virologic improvement in patients receiving once-daily saquinavir/mini-dose ritonavir therapy in clinical practice
218. Increased indinavir levels using twice daily ritonavir/indinavir at 100/800 mg improved virological response even after multiple failure
219. Tolerance and efficacy of indinavir 800 mg plus ritonavir 100 mg bid in addition to nucleoside analogues in HIV infected patients
220. A pharmacokinetic (PK) study to investigate the influence of efavirenz (EFZ) on a bid indinavir (IDV)/ritonavir (RTV) regimen (800/100 mg) in healthy volunteers
221. Increasing adverse events with indinavir dosages and plasma concentrations in four different ritonavir-indinavir containing regimens in HIV-infected patients
222. Preliminary results from indinavir and ritonavir in a once-daily regimen (Merck 103/104)
223. Once-daily indinavir plus ritonavir: Preliminary results from the PIPO study
224. Pharmacokinetic interactions between ritonavir and amprenavir in healthy volunteers
225. Amprenavir 600 mg/ritonavir 100 mg bid or amprenavir 1200/ritonavir 200 mg qd given in combination with abacavir and lamivudine maintains efficacy in ART-naive HIV-1-infected adults over 12 weeks (APV20001)
226. Therapeutic drug monitoring of amprenavir combined with ritonavir as salvage therapy in HIV-1-infected patients
227. The safety and efficacy of ritonavir-boosted amprenavir-based regimen after switch from amprenavir-based HAART
228. The combination of ritonavir and amprenavir in salvage regimens overcomes clinically multiple-drug resistant HIV
229. Absence of resistance to Kaletra (ABT-378/r) observed through 48 weeks of therapy in antiretroviral-naive subjects
230. Kaletra (ABT-378/r) and efavirenz: One-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients
231. Assessement of the pharmacokinetic interaction between ABT-378/ritonavir and efavirenz in healthy volunteers and in HIV + subjects
232. Initial efficacy results from Kaletra (formerly known as ABT-378/r) early-access program
233. Pharmacokinetic evaluation of nelfinavir in combination with nevirapine or ritonavir in HIV-infected children - PACTG 403
234. Kaletra (lopinavir/ritonavir) in HIV-infected children at 48 weeks
235. Baseline genotype and phenotype do not predict response to ABT-378/ritonavir in PI-experienced patients at 24 and 48 weeks
236. Cytochrome P450 3A: Ontogeny and disposition
237. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir containing regimens as salvage therapy in children with human immunodeficiency virus type 1 infection
238. Pharmacokinetics of indinavir and low-dose ritonavir bid in children with HIV-1 infection
239. Dual HIV protease inhibitor (PI) therapy of children
240. Pharmacokinetics (PK) of saquinavir (SQV) and nelfinavir (NFV) in a twice daily (BID) regimen in HIV-infected children
241. Nelfinavir NFV) pharmacokinetics in combination with ritonavir (RTV) in infants and children with advanced HIV disease
242. The Danish Protease Inhibitor study: A randomized study comparing the viological efficacy of 3 protease inhibitor-containing regimens for the treatemnt of human immunodeficiency virus type 1 infection
243. Impact of directly observed therapy on outcomes in HIV clinical trials
244. Differences in viral load outcomes at 90, 180, and 270 days in protease inhibitor (PI)-naive patients treated with dual versus single therapy
245. Efficacy and safety of three different dual PI combinations in pretreated patients